Detalles de la búsqueda
1.
GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer.
Future Oncol;
2022 Oct 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36268941
2.
Au@Pt Core-Shell Nanoparticle Bioconjugates for the Therapy of HER2+ Breast Cancer and Hepatocellular Carcinoma. Model Studies on the Applicability of 193mPt and 195mPt Radionuclides in Auger Electron Therapy.
Molecules;
26(7)2021 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33916671
3.
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
Cancer;
125(22): 3974-3984, 2019 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31318460
4.
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
BMC Cancer;
19(1): 620, 2019 06 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-31234810
5.
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
BMC Cancer;
19(1): 517, 2019 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-31146717
6.
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Breast Cancer Res;
19(1): 16, 2017 02 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28183321
7.
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Lancet Oncol;
17(9): 1230-9, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27501767
8.
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Lancet Oncol;
17(6): 791-800, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27179402
9.
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
N Engl J Med;
366(2): 109-19, 2012 Jan 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-22149875
10.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Lancet;
381(9869): 805-16, 2013 Mar 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-23219286
11.
Adjuvant trastuzumab in HER2-positive breast cancer.
N Engl J Med;
365(14): 1273-83, 2011 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-21991949
12.
Delays in diagnosis and treatment of breast cancer: a multinational analysis.
Eur J Public Health;
24(5): 761-7, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24029456
13.
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lancet Oncol;
14(2): 125-33, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23312888
14.
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
Lancet Oncol;
14(10): 933-42, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23932548
15.
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
Lancet Oncol;
14(1): 72-80, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23246022
16.
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis.
Breast Cancer Res;
15(6): R105, 2013 Nov 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-24192331
17.
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.
Oncologist;
18(7): 812-8, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23814044
18.
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
Lancet Oncol;
13(9): 869-78, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22884505
19.
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Lancet Oncol;
13(1): 25-32, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22153890
20.
The cancer-risk variant frequency among Polish population reported by the first national whole-genome sequencing study.
Front Oncol;
13: 1045817, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36845707